Articles related to TRIPLE-NEGATIVE BREAST CANCER (TNBC)

“For patients with T1cN1-2 or T2-4N0 (stage II or III), early-stage TNBC, the Panel recommends use of pembrolizumab (200 mg once every 3 weeks or 400 mg once every 6 weeks) in combination with neoadjuvant chemotherapy, followed by adjuvant pembrolizumab after surgery.”

Joyce A. O’Shaughnessy, MD provides updates on several key presentations from SABCS, touching on SERD therapy, ribociclib combinations, the datopotamab deruxtecan antibody-drug conjugate targeting overexpression of the calcium signal transducer TROP2, trastuzumab deruxtecan, and more. The MONALEESA phase 3 trial is looking at letrozole + ribociclib vs letrozole + placebo in postmenopausal women with ER+ HER2- advanced breast cancer. The trial arm outperformed the control arm with a median OS of 63.9 months vs 51.4 months respectively at a median follow up of just over 6.5 years. That median OS is the longest reported for any phase 3 trial in advanced breast cancer.

This study reports long term outcomes on CALGB 40603 at a median follow-up of 7.9 years. Event-free survival and other LTOs were not significantly improved with either study drug overall or in studied sub-populations. Results showed that patients with any residual disease had significantly worse outcomes. This finding supports considering adjuvant therapy even in the setting of minimal residual disease.

Trilaciclib (Cosela, G1 Therapeutics), a cyclin dependent kinase 4/6 inhibitor, is already approved in the United States to reduce frequency of chemotherapy-related bone marrow suppression among adults with extensive-stage small cell lung cancer. Now, the FDA has granted fast track designation to the drug for use in combo with chemo for treatment of locally advanced or metastatic TNBC.

Another win for Merck and Keytruda, as the FDA granted accelerated approval to pembrolizumab in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 based on PFS. The FDA also approved a companion diagnostic, PD-L1 IHC 22C3 pharmDx.

According to study results presented at ASCO20 Virtual Scientific Program, a year of maintenance therapy with metronomic capecitabine after standard treatment extended DFS among women with operable triple-negative breast cancer.